Quantum BioPharma (QNTM) Stock News

Quantum BioPharma (NASDAQ: QNTM) has announced a strategic investment in GameStop Corp. (NYSE: GME), purchasing 2,000 shares. This move is part of the company's broader strategy to combat market corruption and enhance shareholder value. The company has recently appointed anti-market manipulation advocates including Kevin Malone as Board Advisor and Terry Lynch as Director.

The company is pursuing legal action against CIBC World Markets and RBC Dominion Securities, seeking damages exceeding $700 million USD for alleged stock manipulation. Additionally, Quantum completed a debt settlement of US$40,000 through the issuance of Class B shares. Malone Wealth Ventures, LLC, which owns approximately 21.8% of Quantum's Class B shares, received 30,000 shares and 60,000 RSUs as consulting compensation.

Quantum BioPharma (NASDAQ: QNTM) has submitted its patented drug candidate Lucid-21-302 (Lucid-MS) to the UK's Innovative Licensing and Access Pathway (ILAP) Passport program. The drug represents a first-in-class treatment for multiple sclerosis, specifically targeting demyelination.

The ILAP program is designed to accelerate the development and approval process of innovative medicines through collaboration between medicine developers, the MHRA, health assessment bodies, NHS, and patients. This submission marks the first step in potentially fast-tracking the drug's development and approval process in the UK.

Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has launched a $5 million Regulation D 506(c) capital raise to fund growth and prepare for a potential IPO. The company has engaged MZ Digital for marketing and Dealmaker as the crowdfunding platform.

Unbuzzd produces a scientifically-proven beverage that accelerates alcohol metabolism and reduces hangover symptoms. The company is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The funds will support direct-to-consumer, distributor, and retail expansion plans.

Quantum BioPharma (NASDAQ: QNTM) has announced the first successful scan of a multiple sclerosis (MS) patient in a joint study with Massachusetts General Hospital (MGH). The study utilizes a novel PET tracer [18F]3F4AP to monitor myelin integrity and demyelination in MS patients. The scanning was performed using a new GE Signa PET-MR scanner, which allows simultaneous PET and MRI imaging, improving spatial and temporal coregistration while reducing patient scan time. This imaging technique could potentially serve as a biomarker to measure the effectiveness of drugs like Quantum's investigational MS drug Lucid-21-302. The PET tracer, developed by Dr. Pedro Brugarolas at MGH, has shown promising results in previous animal and human studies, demonstrating high sensitivity to demyelinated lesions and favorable pharmacokinetics.

Quantum BioPharma (NASDAQ: QNTM) has announced plans to issue special dividend Contingent Value Rights (CVRs) to holders of Class B Subordinate Voting Shares on a 1:1 basis. The CVRs will entitle holders to receive between 10-50% of net proceeds from the company's ongoing litigation against major banks, including CIBC World Markets and RBC Dominion Securities. The litigation seeks damages exceeding $700 million related to alleged stock price manipulation. These CVRs will be non-transferable, non-interest bearing, without voting rights, and redeemable only if the company receives proceeds from the litigation settlement. The exact payout percentage and record date are yet to be determined, and the CVRs will not be listed on any exchange.

Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency investment portfolio to USD $5,000,000 through additional purchases of Bitcoin (BTC) and other digital currencies. The Board of Directors-approved investment demonstrates the company's strategic approach to using cryptocurrencies as both an investment vehicle and a hedge against the dollar. The company has established infrastructure to accept cryptocurrency-based financing and execute various transactions, with all digital assets being held by a compliant custodian. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions while ensuring full compliance with financial and audit regulations.

Quantum BioPharma (NASDAQ: QNTM) has issued a clarification regarding misinformation circulating about its relationship with Unbuzzd Wellness Inc. The company confirms it has not changed its name, contrary to incorrect listings on some trading platforms. Quantum BioPharma is currently the largest shareholder of Unbuzzd Wellness Inc., with significant financial interests including a 7% royalty on revenue (reducing to 3% after $250M), 200M post-split common shares, and an anti-dilution warrant for maintaining 25% ownership. Unbuzzd Wellness Inc. has secured a $1.3M loan from Quantum with 10% annual interest. Additionally, Unbuzzd has hired MNP LLP for PCAOB audits in preparation for a potential IPO. The company also announced a minor debt settlement of $20,930 with Class B Shares.

Quantum BioPharma (NASDAQ: QNTM) has reached a global settlement agreement with its former CEO Dr. Raza Bokhari, resulting in a $2.35 million USD non-dilutive cash payment to the company. The settlement resolves all outstanding disputes stemming from a proxy contest that began in January 2021, including multiple legal proceedings in Canada and the United States. The agreement, signed by current Co-Chairmen & CEO Zeeshan Saeed and Anthony Durkacz, settles various court cases, arbitration awards, and legal claims between the parties. Notable judgments included multiple awards with interest rates ranging from 4% to 6% per annum. All parties acknowledged they acted in shareholders' best interests, with no admission of wrongdoing from any side.

Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), a licensee of Quantum BioPharma (NASDAQ: QNTM), has taken significant steps toward a potential IPO by hiring MNP LLP as its new PCAOB-registered audit firm effective May 20, 2025. This follows the company's February 2025 announcement of retaining a New York investment bank for capital raising and IPO exploration.

The company, known for its unbuzzd™ beverage that accelerates alcohol metabolism and reduces hangover symptoms, is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The company also completed a name change to Unbuzzd Wellness Inc. effective May 23, 2025, with new CUSIP (90429T100) and ISIN (CA90429T1003) numbers.